Compass Therapeutics (CMPX) Depreciation & Amortization (CF) (2019 - 2026)
Compass Therapeutics recorded quarterly Depreciation & Amortization (CF) of $15000.0 in Q1 2026, down 11.76% quarter-over-quarter from $17000.0 in Q4 2025, and down 89.29% year-over-year from $140000.0 in Q1 2025.
Compass Therapeutics' Depreciation & Amortization (CF) history runs 8 years deep, the most recent figure standing at $15000.0 for Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) fell 89.29% year-over-year to $15000.0; the TTM figure through Mar 2026 stood at $151000.0 (down 73.74% YoY), while the FY2025 annual figure was $276000.0, down 53.14% from the prior year.
- Depreciation & Amortization (CF) came in at $15000.0 for Q1 2026 at Compass Therapeutics, down from $17000.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $220000.0 in Q2 2022 to a low of $15000.0 in Q1 2026.
- A 5-year average of $138882.4 and a median of $154000.0 in 2024 frame the typical range for Depreciation & Amortization (CF).
- Across the five-year window, Depreciation & Amortization (CF) jumped 57.26% in 2022 and slumped 89.29% in 2026, its largest moves.
- Compass Therapeutics' Depreciation & Amortization (CF) stood at $195000.0 in 2022, then declined by 17.44% to $161000.0 in 2023, then fell by 13.04% to $140000.0 in 2024, then sank by 87.86% to $17000.0 in 2025, then slipped by 11.76% to $15000.0 in 2026.
- According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $15000.0, $17000.0, and $19000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1,395.22 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 55.90 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 123.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 13.55 Mn |
| 10 | Compass Therapeutics | 418.47 Mn | 223.78 Mn | - | 15,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15,000.00 |
| Mar 31, 2026 | 15,000.00 |
| Dec 31, 2025 | 17,000.00 |
| Dec 31, 2025 | 17,000.00 |
| Sep 30, 2025 | 19,000.00 |
| Sep 30, 2025 | 19,000.00 |
| Jun 30, 2025 | 100,000.00 |
| Jun 30, 2025 | 100,000.00 |
| Mar 31, 2025 | 140,000.00 |
| Mar 31, 2025 | 140,000.00 |
| Dec 31, 2024 | 140,000.00 |
| Dec 31, 2024 | 140,000.00 |
| Sep 30, 2024 | 143,000.00 |
| Sep 30, 2024 | 143,000.00 |
| Jun 30, 2024 | 152,000.00 |
| Jun 30, 2024 | 152,000.00 |
| Mar 31, 2024 | 154,000.00 |
| Mar 31, 2024 | 154,000.00 |
| Dec 31, 2023 | 161,000.00 |
| Dec 31, 2023 | 161,000.00 |
| Sep 30, 2023 | 164,000.00 |
| Sep 30, 2023 | 164,000.00 |
| Jun 30, 2023 | 180,000.00 |
| Jun 30, 2023 | 180,000.00 |
| Mar 31, 2023 | 194,000.00 |
| Mar 31, 2023 | 194,000.00 |
| Dec 31, 2022 | 195,000.00 |
| Dec 31, 2022 | 195,000.00 |
| Sep 30, 2022 | 202,000.00 |
| Sep 30, 2022 | 202,000.00 |
| Jun 30, 2022 | 220,000.00 |
| Jun 30, 2022 | 220,000.00 |
| Mar 31, 2022 | 165,000.00 |
| Mar 31, 2022 | 165,000.00 |
| Dec 31, 2021 | 124,000.00 |
| Dec 31, 2021 | 124,000.00 |
| Sep 30, 2021 | 138,000.00 |
| Sep 30, 2021 | 138,000.00 |
| Jun 20, 2021 | 147,000.00 |
| Jun 20, 2021 | 147,000.00 |
| Mar 31, 2021 | 157,000.00 |
| Mar 31, 2021 | 157,000.00 |
| Sep 30, 2020 | 1.34 Mn |
| Sep 30, 2020 | 1.34 Mn |
| Jun 30, 2020 | 900,000.00 |
| Jun 30, 2020 | 900,000.00 |
| Mar 31, 2020 | 463,000.00 |
| Mar 31, 2020 | 463,000.00 |
| Sep 30, 2019 | 1.60 Mn |
| Sep 30, 2019 | 1.60 Mn |
| Jun 30, 2019 | 1.06 Mn |
| Jun 30, 2019 | 1.06 Mn |